Evotec AG and Ono Pharmaceutical Tighten Collaborations
Evotec AG (Hamburg, Germany) has announced it is extending the protease collaboration it forged with Ono Pharmaceutical (Osaka, Japan) back in March 2008 and is entering into a new discovery agreement with the international drug development company. The new agreement targets an ion channel-ion channels are said to be implicated in cardiovascular, neurological, urological, metabolic, andinflammatory diseases.
Under the new agreement, Evotec will receive research funding for 18 months along with success-based milestones based on progress. Ono, meanwhile, is given worldwide rights to develop and market a product containing the compound discovered.
“Since...the existing collaboration with Evotec targeting a protease has progressed as planned, we are now pleased to enter into a new drug discovery agreement on an ion channel with Evotec utilizing their proprietary drug discovery platform," said Ono's Kazuhito Kawabata, PhD, Managing Director, Research Headquarters. "We anticipate the collaboration will result in identifying a novel drug candidate with a high potential.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
